Pharmacovigilance Planning
The ICH guideline on planning pharmacovigilance activities for the early post-marketing period of a new medicinal product (Step 4, 18 November 2004). E2E defines the safety specification — a summary of the important identified risks, important potential risks, and important missing information — and a structure for the pharmacovigilance plan built on it, plus principles of good practice for the design and conduct of observational studies.
What this does not cover
stated in the document's own scope- Covers the planning of pharmacovigilance activities; the management and expedited reporting of individual cases is the province of E2A and E2D(R1).
- Defines the safety specification and pharmacovigilance plan; the binding EU risk management plan format is set by Regulation (EU) No 520/2012 and GVP Module V.
- Addresses safety planning; risk minimisation measures and their effectiveness evaluation are elaborated in regional guidance rather than in E2E itself.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH E2E is the harmonised guideline on pharmacovigilance planning — how to plan safety activities for a new medicinal product before and during its early post-marketing period. Its central instrument is the safety specification: a structured summary of the important identified risks, the important potential risks, and the important missing information for a product at approval. On that foundation the guideline defines the pharmacovigilance plan: routine pharmacovigilance where the safety profile warrants nothing more, and additional activities — including observational studies — where specific risks or knowledge gaps need active follow-up. An annex describes the pharmacovigilance methods available for those activities, with principles of good practice for designing and conducting observational studies.
Scope & applicability
Pharmacovigilance planning for new medicinal products approaching or entering the market in ICH regions. The safety specification and pharmacovigilance plan it defines became the conceptual basis of the EU risk management plan under GVP Module V.
Legal basis & how it acquires force
An ICH harmonised tripartite guideline, adopted at Step 4 of the ICH process on 18 November 2004, committing the ICH regions to implementation under Step 5. The FDA issued it as guidance for industry in April 2005; the EMA implements it as an ICH scientific guideline, and its concepts were subsequently embedded in the EU pharmacovigilance legislation through the risk management plan required of marketing authorisation applicants.
Document structure
| Part | Covers |
|---|---|
| Introduction | Objectives, background, and the products and situations the guideline addresses |
| Safety specification | The elements summarising important identified risks, important potential risks, and important missing information |
| Pharmacovigilance plan | The structure of the plan, routine pharmacovigilance, and action plans for specific safety concerns |
| Annex — pharmacovigilance methods | Observational and other methods available for post-approval safety activities, with good-practice principles for study design and conduct |
Key requirements
- Prepare a safety specification summarising important identified risks, important potential risks, and important missing information
- Build a pharmacovigilance plan proportionate to the safety specification — routine pharmacovigilance where sufficient, additional activities where not
- Design observational studies within the plan according to good practice principles
Implementation tips
- Keep the safety specification a living document — the EU RMP and the PSUR/PBRER family all draw on the same risk inventory, so one maintained source prevents divergence
Revision notes
Adopted at Step 4 on 18 November 2004 and unrevised since; the EU risk management plan (GVP Module V) and the PBRER (E2C(R2)) build on its safety-specification concept.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
E2E supplied the conceptual skeleton that later regional instruments formalised: the EU risk management plan under GVP Module V is a direct descendant of its safety specification and pharmacovigilance plan, and the periodic benefit-risk evaluation report of ICH E2C(R2) draws on the same structured risk inventory. Within the ICH E2 family it is the planning guideline, sitting alongside E2A (clinical safety definitions), E2D(R1) (post-approval case management), and E2B(R3) (electronic transmission).
ICH E2E: frequently asked questions
Quick answers to common questions about ICH E2E.
What is the safety specification in ICH E2E?
A structured summary, prepared at approval, of a product's important identified risks, important potential risks, and important missing information — the knowledge gaps that matter, such as populations not studied. It is the foundation on which the pharmacovigilance plan is built.
How does ICH E2E relate to the EU risk management plan?
The EU RMP grew out of E2E: GVP Module V structures the RMP around the same safety specification and pharmacovigilance plan the guideline defines, and adds the EU-specific risk-minimisation part. A team drafting an RMP is working with E2E concepts in a legally required format.
When was ICH E2E adopted?
The guideline reached Step 4 of the ICH process on 18 November 2004, and the regions implemented it in 2005 — the FDA published its version as guidance for industry in April 2005.
Does ICH E2E require additional pharmacovigilance activities for every product?
No. Where the safety specification raises no concern needing active follow-up, routine pharmacovigilance is sufficient. Additional activities — such as observational studies — are proposed only for specific risks or missing information that routine surveillance cannot adequately address.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.